Healthcare Professionals

Updated information and resources for doctors, researchers, and other healthcare professionals.

This is a partnership between healthcare professional, patient and Pharmamar.

Our partnerships with healthcare professionals

Our partnerships with healthcare professionals

"We are honored by the trust placed in us and our medicines by healthcare professionals all over the world; helping them care for their patients."

Ali Zeaiter, M.D

Director of Clinical Development

"This partnership is essential to what we do and our mission statement reflects this: Our North Star is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines."

Ali Zeaiter, M.D

Director of Clinical Development

"We will collaborate with you in helping you care for your patients, as well as to advance medicine with novel new options for patients."

Ali Zeaiter, M.D

Director of Clinical Development

"We are motivated to offer hope to patients with unmet medical needs, including in rare diseases, and are accountable to you, to patients as well as ourselves to deliver on this."

Ali Zeaiter, M.D

Director of Clinical Development

Our Marketed Products

YONDELIS® (Trabectedin)

Approved for soft tissue sarcoma, or platinum resistant ovarian cancer in combination with Doxil®/Caelyx®, depending on your country. Trabectedin is a multimodal, synthetically produced antitumor agent, originally derived from the sea squirt, ecteinascidia turbinata. The drug exerts its activity by targeting the transcriptional machinery and impairing DNA repair.

ZEPZELCA® (Lurbinectedin)

Approved for relapsed small cell lung cancer in USA, UAE, Canada and Australia. Zepzelca (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent.

APLIDIN® (Plitidepsin)

Approved for relapsed/refractory multiple myeloma in Australia only. Plitidepsin (Aplidin®) is an anticancer agent of marine origin, originally obtained from the ascidian aplidium albicans. It specifically binds to the eEF1A and targets the non-canonical role of this protein, resulting in tumor cell death via apoptosis (programed death).

Open Clinical Trials

Lurbinectedin

Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors.

Learn more: Lurbinectedin

Plitidpesin

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection (Neptuno).

Learn more: Plitidpesin

Compassionate access to unaproved drugs

We try to allow early access to our medicines when they look promising. PharmaMar has deployed compassionate use programs in many countries to enable early access, to patients with severe conditions and limited options. For example, our current compassionate use program has enrolled over 2500 patients from many countries.

Find out if such a program exists in your location by requesting information from us on compassionate use programs; email either compassionateuse@pharmamar.com for oncology or compassionateuse-virology@pharmamar.com for virology, stating your interest and country of residence. The enquiry must come from a healthcare professional using their institutional email address.

Unapproved drugs

Indications

Ecubectedin

We are prepared to carry out the development of our products consistently, with rigor to the scientific process, under the dictated specifications. We are committed to supporting medical and scientific research aimed at advancing disease knowledge and patient care.

PM14 (Ecubectedin)

A new chemical entity that forms DNA adducts which specifically inhibit RNA synthesis and active transcription of protein-coding genes. Antitumor activity has been demonstrated in vitro in several cell lines (e.g. lung, kidney, prostate and leukemia), and in vivo in mice bearing xenografted human-derived tumors (soft tissue sarcoma, small cell lung cancer, multiple myeloma, as well as ovarian, gastric, breast, and renal cancers).

Indications

We are prepared to carry out the development of our products consistently, with rigor to the scientific process, under the dictated specifications. We are committed to supporting medical and scientific research aimed at advancing disease knowledge and patient care.

Ecubectedin

PM14 (Ecubectedin)

A new chemical entity that forms DNA adducts which specifically inhibit RNA synthesis and active transcription of protein-coding genes. Antitumor activity has been demonstrated in vitro in several cell lines (e.g. lung, kidney, prostate and leukemia), and in vivo in mice bearing xenografted human-derived tumors (soft tissue sarcoma, small cell lung cancer, multiple myeloma, as well as ovarian, gastric, breast, and renal cancers).

Investigator Sponsored Trials

”We aim to partner with healthcare professionals in their task of providing the best care to their patients, maintaining high ethical standards and commitments to innovation and excellence in the generation of scientific knowledge”

Maria Jose Pontes Valero, International Associate Director, Medical Affairs

Investigator Sponsored Trials

Medical information

Resource for healthcare providers and patients to request timely medical information relating to PharmaMar products. Please fill out the form below with your specific request which will be routed to a member of our Medical Affairs team.

please, insert your first name
please, insert your last name
please, choose an option
please, choose a country
please, choose a community
please, choose a drug
please, write some message
Please, accept the Privacy Policy

Pharmacovigilance

Pharmacovigilance is a top priority for us at PharmaMar is that our medicines perform as expected and that is why we monitor all of our medicines from the first patient to get it until its last.

Report now->

0.4983 seconds.